🔎 Trials Near Me

Home › Chronic Lymphocytic Leukemia › NCT06784167

Vaccine Responses in Patient With Multiple Myeloma and Non-Hodgkin Lymphoma After CAR-T Treatment

RecruitingObservational study

Vaccine Responses in Patient With Multiple Myeloma and Non-Hodgkins Lymphoma Post CAR-T Treatment

Who can join

Ages 18 and older · All sexes

Full eligibility criteria
Inclusion Criteria:

* \* Willingness to provide written informed consent before any study-specific procedures or activities are performed

  * Age ≥ 18 years of age, at the time of consent
  * Documented, histologically or cytologically confirmed diagnosis of multiple myeloma (MM), diffuse large B cell lymphoma (DLBCL),follicular lymphoma (FL), mantle cell lymphoma (MCL), chronic lymphocytic leukemia (CLL), or small lymphocytic lymphoma (SLL), or primary mediastinal B cell lymphoma (PMBL). All number of prior lines of therapy are allowed
  * History of prior vaccination against common VPD
  * Approved by managing physician for CAR-T therapy, with preparative conditioning planned within the next 90 days
  * Approved by managing physician for revaccination against Streptococcus pneumoniae or tetanus

Exclusion Criteria:

* \* Ongoing use of immunosuppressive agents or plans for immunosuppressive therapy that would interfere with interpretation of study endpoints

  * Uncontrolled, intercurrent illness including, but not limited to, systemic infection, symptomatic congestive heart failure, unstable angina pectoris, or psychiatric illness/social situations that would limit compliance with study requirements or make the study procedures unadvisable

About the study

This study evaluates immune responses after CAR-T therapy to find out if CAR-T therapy reduces the effectiveness of the vaccines (vaccine immunity) against diseases such as measles, mumps and rubella, among others in patients with multiple myeloma and non-Hodgkin lymphoma.

What is being tested

Sponsor: OHSU Knight Cancer Institute · Participants: 45 · Started: Mar 10, 2025

Contact the study team

Official record on ClinicalTrials.gov — NCT06784167

Locations in the U.S.

OregonOHSU Knight Cancer Institute, Portland

Conditions

From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.